Dexmedetomidine for Maintaining Sedation

During prolonged mechanical ventilation, sedation with midazolam or propofol is associated with serious adverse effects. Jakob and colleagues assessed the efficacy of dexmedetomidinean 2-agonist sedativecompared with either midazolam or propofol in 2 multicenter randomized trials that involved 998 patients expected to require more than 24 hours' mechanical ventilation. Among the authors' findings was that dexmedetomidine was not inferior to midazolam or propofol in maintaining light to moderate sedation or in reducing total ventilation duration compared with midazolam. However, dexmedetomidine was associated with more adverse events. In an editorial, Wunsch discusses the costs and benefits of sedative options for critically ill patients undergoing mechanical ventilation.

(ARTICLE) (ARTICLE)

Epinephrine is widely used in resuscitation of patients with out-of-hospital cardiac arrest; however, its effectiveness is not established. Hagihara and colleagues analyzed registry data from 417188 patients with out-of-hospital cardiac arrest to assess the relationship between prehospital epinephrine use and mortality and functional status among survivors. The authors report that prehospital epinephrine use was associated with increased return of spontaneous circulation before hospital arrival but decreased the likelihood of survival at 1 month or survival with good functional status. In an editorial, Callaway discusses the evidence that epinephrine use during cardiopulmonary resuscitation may not improve patient-oriented outcomes.

(ARTICLE) (ARTICLE)AND AUTHOR AUDIO INTERVIEW

Immunosuppressive induction therapyroutine in organ transplantsreduces the risk of organ rejection but is associated with adverse effects. Infusion of bone marrowderived mesenchymal stem cells, which have immunoregulatory effects, may offer an alternative immunosuppressive approach. In a randomized trial of 159 patients undergoing living-related kidney transplants, Tan and colleagues found that compared with conventional antiinterleukin 2 receptor antibodybased therapy, a regimen that involved infusion of autologous mesenchymal stem cells was associated with a lower incidence of acute rejection and better renal function at 1 year.

(ARTICLE)

The use of anesthesiologists or nurse anesthetists to administer procedural sedation during outpatient endoscopies increases costs. In a retrospective analysis of claims data from 1.1 million Medicare beneficiaries and 5.5 million commercially insured patients, Liu and colleagues found that utilization of anesthesia services during upper endoscopies and colonoscopies increased from approximately 14% in 2003 to more than 30% in 2009. The majority of anesthesia services were provided to low-risk patients and varied across geographic regions. In an editorial, Fleisher discusses factors that may contribute to increased use of anesthesia services for patients undergoing endoscopy procedures.

(ARTICLE) (ARTICLE)AND AUTHOR VIDEO INTERVIEW

Mrs N, a 75-year-old woman, has a several-year history of hearing loss, which is more bothersome to her family than herself. Pacala and Yueh discuss the prevalence, etiology, and consequences of hearing loss in older patients; its evaluation and treatment, including the selection and fitting of hearing aids; and special challenges to effective hearing aid use among older adults with multiple comorbidities.

Read more:
This Week in JAMA [This Week in JAMA]

Nigeria launches its first ever bone marrow registry, which should make it easier to find matches for black people around the world.

By Jef Akst | March 19, 2012

Bone marrow transplants, or hematopoietic stem cell transplantations (HSCT), treat more than 70 different diseases, including some types of leukemia, lymphoma, and sickle cell anaemia. But such treatment often requires the matching of strangers for their human leukocyte antigen (HLA) tissue type. And while 70 percent of Caucasian patients are successfully matched, only 17 percent of black people in the United States are as lucky, according to The New York Stem Cell Foundation, likely because only 8 percent of donors in US registries are black.

The Bone Marrow Registry in Nigeria (BMRN), the countrys first ever bone marrow registry and the continents second (South Africa having the only other accredited registry), aims to change all that. The registry follows the excitement surrounding Nigerias first bone marrow transplant last October, in which a young sickle cell anaemia patient received bone marrow from a sibling. In addition to providing an invaluable service to the people of Nigeria, the registry, launched by Seun Adebiyi of Yale University, should help black patients around the world find matched donors. The launch of the registry was discussed at the NCD Child Conference currently being held in San Francisco.

Adebiyi also plans to establish another Nigerian source for stem cell transplantsan umbilical cord blood bank. With as little as $75,000, we could build [a cord blood bank] in Nigeria by the end of this year instead of discarding this valuable source of stem cells, he said in a Lancet press release. There are almost 400 distinct ethnic groups and over 154 million people in Nigeria alone, and there is a huge population of umbilical stem cells just waiting to be banked in the maternity wards of hospitals around the country.

By Cristina Luiggi

An Italian university is investigating whether a professor was right to teach a course denying a causal link between HIV and AIDS.

By Hannah Waters

Replacing immune cells in a mouse model of Rett syndrome, a developmental brain disorder, improved symptoms, suggesting a new target for treatment.

By Megan Scudellari

See the original post here:
New African Bone Marrow Registry

GOLDEN, Colo., March 20, 2012 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (OTCQB:VODG.PK - News), dba Vitro Biopharma, has recently received approval for its presentation entitled "GMP Cell Culture Media for Expansion of MSCS Prior to Allogeneic or Autologous Transplantation." The Company recently expanded its stem cell media products to include clinical grade MSC-Gro(TM) media for use in clinical trials of stem cells. The Company will present its current findings at the annual meeting of the International Society of Cellular Therapy (ISCT) in Seattle, Washington this coming June. To get more information regarding the International Society of Cellular Therapy visit http://www.celltherapysociety.org/

Vitro Biopharma has developed a series of products to support clinical application of adult stem cells known as mesenchymal stem cells (MSCs) that are completely divorced and different from ethically contentious embryonic stem cells. MSCs are derived from numerous adult tissue sources including bone marrow, blood, adipose tissue, teeth, etc and show considerable promise in clinical applications especially for treatment of injury and diseases affecting joints, bone, ligaments and tendons. There are over 200 ongoing clinical trials of MSCs to study potential treatment of diabetes, Parkinson's disease, organ transplant rejection, osteoarthritis, MS, spinal cord injury, stroke, myocardial infarction, cardiovascular disease, liver degeneration, COPD and other medical conditions.

Vitro Biopharma will present the current status of its clinical grade MSC-Gro(TM) Brand of culture medium for growth and differentiation of MSCs at the ISCT meeting. Through its extensive research and experience with cell culture media, Vitro Biopharma has developed highly competitive media that is suitable for clinical applications. Critical characteristics are that they are serum-free, chemically-defined and free from animal-derived components. Furthermore, it is essential that serum-free media perform the same as formulations containing contain blood serum, a complex mixture of biologically active components with intrinsic variability from batch to batch and safety issues regarding potential infectious agents. Vitro will present its results regarding each of these points and the status of FDA approval of its clinical products.

Dr. Jim Musick, Vitro's President & CEO, said, "We are very pleased to be approved for presentation at the ISCT Annual Meeting. It is apparent from the reported widespread efficacy of MSCs in clinical trials and the low incidence of adverse effects that there is potential to achieve regulatory approval for advanced treatment of many diseases, injuries and cellular degenerative conditions. Our new clinical products expand our offering of tools to support stem cell research by providing highly competitive new products for clinical studies including our serum-free, animal-free and chemically defined MSC-Gro(TM) Brand of media formulations optimized for human MSC self-renewal & lineage-specific differentiation, together with LUMENESC(TM) high performance assays of stem cell quality, potency and response to toxic agents. We intend to leverage our current advances in human medical MSC-based treatments to offer products for treatment of horses, dogs and cats. The results of MSC therapy in animals may also provide safety and efficacy data to support human clinical studies."

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG.PK - News) (http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells(TM)" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development(TM)", including human mesenchymal stem cells and derivatives, MSC-Gro(TM) optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix(R), Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute LUMENESC(TM) and LumiSTEM(TM) quantitative assays for determination of stem cell quality, potency and response to toxic agents.

The Vitro Biopharma logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12086

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

Originally posted here:
Vitro Biopharma Receives Approval for Presentation to the International Society for Cellular Therapy

-- Allure Image Enhancement Among First to Offer the Stem Cell Facelift and PRP Therapy in the Inland Empire --

UPLAND, CA (PRWEB) March 19, 2012

Stem Cell Facelift with PRP Therapy provides an amazing full facial restoration and can simulate the effects of a face lift, brow lift, and total facial rejuvenation in one sitting. In addition, the benefits of the PRP Therapy with growth factors enhance stem cell survival, giving long lasting and potentially permanent results, says John Grasso MD, Medical Director at Allure Image Enhancement. I find these procedures to be an exciting new approach to the world of dermal fillers. Rather than using lab derived products, patients can enjoy the benefits of volume and longevity from their own cells.

Stem Cells often thought of as controversial and futuristic, are the latest beauty secret now available. Although injectable wrinkle treatments are very popular, there are many who shy away from putting anything foreign into their face. The two most common requests my patients ask me when it comes to anti-aging rejuvenation are: 1. Is there something natural I can use? and 2. Is there anything that lasts longer? Autologous fat transfer enhanced with stem cells and platelet rich plasma is going to change the world of Anti-Aging skin care, says Mina Grasso NP, owner of Allure Image Enhancement. For those who do not have adequate fat deposits or choose not to have autologous fat transfer can still benefit from the healing and repair response of various growth factors and cytokines with PRP alone or combined with manufactured fillers.

Fat transfer has been around for many years and may yield inconsistent results: 50% of the transferred fat usually breaks down within 2 years. Fat is an abundant source of mesenchymal stem cells. The difficulty is that in obtaining fat using Liposuction, up to half of the natural stem cells may be damaged. By adding additional autologous stem cells to the suctioned fat, it closer approximates the original concentration of stem cells in fat in the body and may aid the transplanted fat cells in surviving longer. Platelet Rich Plasma (PRP), which contains growth factors and cytokines, stimulates a repair response in soft tissue when added to the stem cell enhanced fat cells. The grafted fat and stem cells as well as surrounding local cells are activated by these growth factors to generate new growth that plumps up sagging areas. The growth factors enhance the quality of skin on the surface and repair sun damage and skin color irregularities.

Using this revolutionary new method, stem cells show promise in regenerating collagenproducing fibroblasts, cartilage, muscle and even bone cells. Research trials are under way using stem cells to repair other damaged tissue such as lungs, knees, and hearts and reverse neurological degenerative diseases. Stem Cell Facelift with PRP results in long-lasting volume in the treated area, and patients can start to see improvement in skin texture a healthy glow as soon as three weeks following treatment, with dramatic results occurring over a period of two to four months and lasting for years..

About Allure Image Enhancement, Inc.

Founded by Mina Grasso, RN, MSN, FNP-C, and her husband John Grasso MD. Allure Image Enhancement, Inc., for 15 years has served the Inland Empire with the latest in medical esthetics, providing services such as Botox Cosmetic, Restylane, Dysport, Juvderm, Latisse, Laser Hair Removal, Tattoo Removal, Laser Skin Rejuvenation, Vein Treatment, Body Shaping, and many more services.

Contact:

Nicholas Rodgers, CAC

More here:
Breakthrough Beauty Procedure Using Your Own Stem Cells Offered in the Inland Empire

TechCentral

Synthetic biology: genetic engineering on steroids TechCentral You can also leave a comment below this article Whether or not we agree with it, we're all pretty used to the idea of genetic engineering. Our food chain is full of GM crops and pretty soon we may be genetically modified ourselves. Synthetic Biology BrouhahaGenetic Engineering News (blog) all 3 news articles »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

NOLA.com

Audubon center in Algiers logs another breakthrough in genetic engineering of ... NOLA.com By Mark Waller, The Times-Picayune A year after introducing the first pair of rare African black-footed kittens conceived through in vitro fertilization, the scientists at the Audubon Center for Research of Endangered Species in Algiers have announced ... and more »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

msnbc.com

Environmental groups call for tighter regulation of 'extreme genetic engineering' Washington Post Led by the environmental advocacy group Friends of the Earth, the coalition also called for stronger government regulations over “extreme genetic engineering” and a moratorium on the commercial use and release of lab-created organisms. 111 organisations call for more controls over use of synthetic biologyMTBeurope all 8 news articles »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Nature.com

Merck & Co. to Invest $90M to Set Up New Translational Med Center in San Diego Genetic Engineering News Merck & Co. will join with a chemist-turned-biotechnology entrepreneur to launch the California Institute for Biomedical Research (Calibr) in La Jolla, CA, with the goal of advancing discoveries into new drugs. Merck will provide the new nonprofit ... Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to ...MarketWatch (press release) Deals and Moves: March 16NJBIZ Merck collaboration will create non-profit drug research instituteThe Star-Ledger - NJ.com all 64 news articles »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Stem cell researchers and institutions throughout the state are likely to be affected by proposed changes – to be discussed online publicly Tuesday – dealing with how the California stem cell agency will handle its $3 billion in grants.

An important online session – open to all interested parties – comes up then, but advance registration is required.

The proposals are wide-ranging and detailed. The nearly 500 recipients of CIRM grants should examine them closely in addition to any persons seriously interested in California stem cell affairs. The changes deal with such subjects as milestones for research grants, indirect costs, travel costs, withholding payments for failure to file a progress report and much, much more.

Here is a link to the main page for all this, which has instructions on how to register for the online session along with links to the changes and their rationale.

(Editor's note: This item was filed from the Rio Sabana in the Darien in Panama when we found a weak Internet cellular link. We are still underway so postings are unlikely between now and later this month.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

A NEW stem cell therapy treatment to develop new bones for patients with bone loss and new skin for recipients of plastic surgery has been developed, doctors from Shanghai No.9 People's Hospital announced yesterday.

In the procedure, medical staff use a special machine to collect stem cells from a patient's blood. The stem cells adhere to a base made of a special biological material.

The stem cells are then transplanted into the patient's body, where they grow into either new bones or skin tissue, while the base is absorbed by the human body.

"So far the practice has been successful in treating patients with bone and skin loss," said Dr Dai Kerong from Shanghai Jiao Tong University's translational medicine institute at Shanghai No.9 hospital. "The stem cell technology will be used to develop corneas for blind people as well as treating heart attack and stroke patients by developing new heart and cerebral tissue."

The technology is patented in China and abroad and will be licensed within one or two years, according to Dai.

China has established 51 translational medicine centers to boost the introduction of laboratory research into clinical use.

The complicated procedures and documentation required often prevent doctors from introducing lab success into clinical practice.

Dai said one reagent developed by No. 9 hospital's doctors for in vitro fertilization received a license in Europe within six months and has been used in clinical practice "while this would take at least five years in China."

Go here to read the rest:
Eastday-Big stem cell breakthrough

LEUVEN, BELGIUM--(Marketwire -03/15/12)- TiGenix NV (EURONEXT: TIG) today gave a business update and announced financial results for the full year 2011.

Business highlights

Financial highlights

"TiGenix has created a new and strong basis in 2011 on which we can build going forward and we have strengthened our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We have delivered on our promises: we have obtained national reimbursement for ChondroCelect in Belgium and made progress in other European markets. We advanced all clinical stem cell programs on plan, and raised substantial funds from specialized healthcare investors and through non-dilutive financing. Today, TiGenix is well-positioned to reach the next value-enhancing inflection points."

Business Update

Successful integration of Cellerix reinforces leadership position in cell therapyIn May 2011, TiGenix closed the business combination with the stem cell therapy company Cellerix, creating the European leader in cell therapy. During 2011 the Company succeeded in rapidly integrating both entities. The Company now combines top line revenues with an advanced pipeline of clinical stage regenerative and immuno-modulatory products. TiGenix's operations are supported by a strong commercial and manufacturing infrastructure for advanced cell therapies, an experienced international management team and a solid cash position.

As a result of the merger, the Company's development focus has shifted from early stage preclinical programs towards a number of highly promising clinical stage products for inflammatory and autoimmune disorders of high unmet medical need, each addressing markets in excess of EUR 1 billion. TiGenix product pipeline is based on a proprietary stem cell platform that exploits expanded allogeneic (donor-derived) adult stem cells derived from human adipose (fat) tissue ('eASCs'). The platform has been extensively characterized in line with requirements of the European Medicines Agency (EMA) and is supported by exhaustive preclinical and CMC packages.

Given its focus on cell therapy, TiGenix is in the process of divesting its ChondroMimetic franchise, which is based on a biomaterial platform. To be able to concentrate on its core business and move forward with a clean slate, TiGenix has decided to write-off the intellectual property related to the OrthoMimetics acquisition.

ChondroCelect commercial roll-out progressing with first national reimbursementChondroCelect obtained reimbursement in Belgium in May 2011, and is today available in 22 specialized treatment centers.

TiGenix is selling ChondroCelect in the UK, the Netherlands, Germany, and Spain under managed access and private insurance schemes, while pursuing national reimbursement in these countries and France.

More:
TiGenix Reports Full Year 2011 Financial Results

WASHINGTON, March 13, 2012 /PRNewswire/ -- TEDMED, http://www.TEDMED.com, the annual gathering where science, medical and technology leaders focus on "imagination, innovation and inspiration" to advance the art of health and medicine, today announced two new programs that will vastly increase the size and scope of its audience.

TEDMED is the world's only TED-licensed event focused solely on innovation and breakthrough thinking across all of health and medicine. It will be held at the John F. Kennedy Center for the Performing Arts in Washington, D.C., April 10 - 13.

Speakers, attendee-Delegates and participants will range from biologists (Dr. E.O. Wilson) and writers (Ben Goldacre), to physicists (Albert-Laszlo Barabasi) and public health leaders like the director of the National Institutes of Health (Dr. Francis Collins). Topics to be explored by TEDMED speakers will include neuroscience, microbiology, surgery, oncology, stem cell therapy, bad science, Alzheimer's, robotics, game science, wearable tech, disease evolution, patient choice, virtual anatomy models, the nature of imagination, and dozens more.

For the first time this year, TEDMED will offer a free simulcast, TEDMEDLive, to teaching hospitals, medical schools, research institutions, university life science departments, state and federal government agencies, health-oriented corporations and non-profits across the nation. Participants, forecasted at more than 50,000, will be able to view a high-definition live stream of each presentation and performance. Using the TEDMED Connect mobile app, remote participants can also ask questions of the speakers in real time, which may be answered directly from the TEDMED stage.

Over 2,000 TEDMEDLive simulcast locations will participate, including institutions such as: Case Western Reserve University, Harvard University, University of California (Davis and Irvine), University of Pennsylvania, University of Washington, University of Virginia, Tulane University, Vanderbilt University and Yale University.

Another new TEDMED initiative is the Front-Line Scholarship Program, which offers up to $2 million in half- and full-fee scholarships to those leaders and innovators who are on the front lines of health and medicine. It assists those who would both contribute to the TEDMED conference as attendees, and would greatly benefit from joining the conference in Washington, D.C. in person as a Delegate. The Front-Line Scholarship Program is underwritten by the TEDMED Patron Fund, whose major contributors include Humana and The California Endowment.

"TEDMED is for everyone who is passionate about the future of health and medicine," said Jay Walker, curator of TEDMED."Accordingly, TEDMED is committed to bringing even more expertise and perspective to the table for a national discussion of health and medicine, regardless of ability to pay through our Front-Line Scholarship program. Front-Line Scholarships will permit the broadest possible group of healthcare providers, first responders and other contributors to attend so they can share even more ideas that will save lives."

More than 1,200 TEDMED onsite attendees including researchers, physicians, technologists and policy experts will foster cross-disciplinary collaboration and learning at the Kennedy Center this April. Institutions of excellence represented by speakers and attendees will include The American Cancer Society, The American Red Cross, Biodigital Systems, The Boulis Laboratory, Brandeis University, Brigham and Women's Hospital, The California Institute of Technology, Center for Complex Network Research, The Centers for Disease Control and Prevention, Duke University, Emory University, Harvard University, mc10, Methodist Institute for Technology, Innovation, and Education, The National Institutes of Health, New York University, Penn State University, Quest Diagnostics, The Center for Alzheimer Research and Treatment, Reuters Health, Children's Hospital Boston, The U.S. Department of Health and Human Services, and the Young Professionals Chronic Disease Network.

TEDMED Speaker List (as of 3/12/2012)

Additional speakers will be announced prior to the conference start date.

Read the original here:
TEDMED 2012 Conference Offers $2 Million in Scholarships to Health and Medicine Leaders and Innovators; Free National ...

12-03-2012 17:41 Dr.Mark Newkirk is once again on the cutting edge of medicine. Newkirk Family Veterinarians now offer STEM CELL THERAPY for pets. Dr. Mark Newkirk combines traditional medicine and surgery with Holistic Alternatives to access the best of both worlds. As a Veterinarian, Dr. Newkirk has been serving Southern New Jersey for over 25 years. He is extensively trained in medicine and surgery and also is skilled in the care of exotic pets such as reptiles and birds. Dr. Newkirk is also one of only 5 doctors in the country currently undergoing training by the nationally renowned Dr. Martin Goldstein, the author of "The Nature of Animal Healing", and founder of immuno-augmentative therapy for animals, a true alternative cancer therapy. Dr. Newkirk is a member of American Holistic Veterinary Medical Society, the American Veterinary Medical Association, New Jersey Veterinary Medical Association and the Colorado Veterinary Medical Association. For more information check out Stem Cell Therapy on The Animal Planet's dogs 101 http://www.youtube.com

The rest is here:
Stem Cell Therapy at Newkirk Family Veterinarians - Hunter's Story - Video

Public release date: 12-Mar-2012 [ | E-mail | Share ]

Contact: Sarah Jackson press_releases@the-jci.org 919-684-0620 Journal of Clinical Investigation

EDITOR'S PICK Restoring what's lost: uncovering how liver tissue regenerates

The liver is unique among mammalian organs in its ability to regenerate after significant tissue damage or even partial surgical removal. Laurie DeLeve and her colleagues at the University of Southern California in Los Angeles wanted to better understand which cells are specifically responsible for driving liver regeneration. A specialized cell type, known as liver sinusoidal endothelial cells, has generally been thought to promote regeneration of liver tissue. However, the DeLeve team suspected that stem cells and progenitor cells, which have the capacity to differentiate into mature cell types, might be responsible for stimulating liver regeneration by generating hepatocyte growth factor. Using a rat model system, they first identified the presence of stem and progenitor cells that give rise to liver sinusoidal endothelial cells in both the liver and the bone marrow. They next sought to determine which population of stem and progenitor cells are required for regeneration. DeLeve and colleagues found that the bone marrow-derived cells were not required for liver cell proliferation in the absence of damage. In contrast, following surgical removal of a portion of the rat liver, an infusion of bone marrow-derived progenitor cells was required for liver regeneration. These results improve our understanding of how liver tissue can regenerate following damage and may shed light on liver complications in patients with suppressed bone marrow tissue.

TITLE: Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats

AUTHOR CONTACT: Laurie D. DeLeve University of Southern California Keck School of Medicine, Los Angeles, CA, USA Phone: 323-442-3248; Fax: 323-442-3238; E-mail: deleve@usc.edu

View this article at: http://www.jci.org/articles/view/58789?key=21e2857b21106f232595

ONCOLOGY New Determinant of Human Breast Cancer Metastasis Discovered

Researchers at the University of Kentucky's Markey Cancer Center in Lexington, KY have provided new insight as to why the most severe subtype of breast cancer in humans frequently metastasizes. Tumor cells can exploit a cellular program that promotes cell migration and reduces adhesion between cells to spread to distant sites in the body (metastasis). This cellular program, known as the epithelial-mesenchymal transition, is normally restricted to wound healing, tissue remodeling and embryonic development. Increasing cell motility requires a decrease in E-cadherin, which functions to promote cell-cell adhesion. Led by Binhua Zhou, the research team identified G9a as a major repressor of E-cadherin expression. They found that G9a interacts with Snail, which can repress gene expression, to modify the E-cadherin promoter and block expression of the E-cadherin gene. Their findings establish that G9a is an important determinant of metastasis in the most severe sub-type of breast cancer, and suggest the development of new therapeutics targeting this pathway could potentially disrupt the metastatic disease.

TITLE: G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer

Read the original post:
JCI early table of contents for March 12, 2012

CLEARWATER, FL--(Marketwire -03/12/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA).

Biostem CEO, Dwight Brunoehler stated, "The Company is now positioned for growth and international expansion. Adding a world class team of clinical, laboratory, and regulatory experts for our Scientific and Medical Board of Advisors to guide our pursuits is essential. Dr. Prendergast brings a wealth of experience not only in the scientific aspects of stem cell use in regenerative medicine, but also in forging research and international economic development opportunities."

Dr. Prendergast is a busy clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in biophysics and Psychology, as well as his medical degree, at Pennsylvania State University. His general surgery residency was for five years at the University of Massachusetts Medical School. His cardiothoracic surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included pediatric cardiac surgery at Children's Hospital of LA, along with thoracic transplant fellowships at University of Southern California in Los Angeles and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of their staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transplantation and Mechanical Assistance.

Regarding his appointment to the Biostem U.S. Scientific and Medical Board of Advisors, Dr. Prendergast said, "I am looking forward with excitement to working again with Dwight at Biostem. The expansion plan is sound, well paced, and will afford improved quality of life opportunities to many people around the world."

About Biostem U.S., Corporation

Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Kerry D'Amato, Marketing Director at 727-446-5000.

View original post here:
Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of ...

By Jonathan Benson

Food-borne illness outbreaks and the growing prevalence of antibiotic-resistant "superbugs" are two very serious societal problems for which researchers say they are actively looking for viable solutions. But one such solution found right in nature is coriander oil, which has been found to kill a number of different bacterial strains, as well as aid in digestion and treat the symptoms of food poisoning.

Dr. Fernanda Domingues and her colleagues from the University of Beira Interior in Portugal tested the effects of coriander oil, an essential oil extracted from the seeds of the coriander plant, also known as cilantro, on twelve different bacterial strains, including Escherichia coli (E. coli), Salmonella enterica, and methicillin-resistant Staphylococcus aureus (MRSA), the infamous hospital superbug. Read more...

AyurGold for Healthy Blood

Source:
http://feeds.feedburner.com/integratedmedicine

Genetic Engineering News

Biopharma Will Need More than New Law to Embrace Crowdfunding Genetic Engineering News Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, ... and more »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Scientific American

Seeing the invisible field: genetic engineering gives yeast the gift of ... SmartPlanet.com (blog) What all this means is that magnetism, that elusive sense that so many animals lack, could potentially be induced through some simple genetic engineering. Making cells magnetic could have uses for therapy and bioengineering. Magnetic YeastScientist all 11 news articles »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Tweet 

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog